IL17A and in situ carcinoma: Indeed, previous studies have determined an increased frequency of Th17 cells and GM-CSF–producing Th cells in the blood and CSF of MS and CIS patients during active disease (45, 46), and have further associated the frequency of effector memory Th17 cells as well as IL-17a levels with disease severity (EDSS) (45, 47).